Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation

Tomás J. González-López,1 Lourdes Vázquez,1 Teresa Flores,2 Jesus Fernando San Miguel,1 Ramón García-Sanz1
1Hematology Department; 2Pathology Service, University Hospital of Salamanca, Salamanca, Spain

Abstract

A 63-year-old woman presented with progressive renal insufficiency, until a glomerular filtration rate (GFR) of 12 mL/min. A renal biopsy demonstrated glomerular deposition of immunoglobulin κ light chain. The presence of a small population of monoclonal plasmacytes producing an only light κ monoclonal component was demonstrated and Bortezomib and Dexamethasone (BD) was provided as initial therapy. After seven courses of therapy, renal function improved without dialysis requirements up to a GFR 31 mL/min. Under haematological complete response (HCR) the patient underwent high dose of melphalan (HD) and autologous peripheral blood stem cell transplant. Fifty-four months later the patient remains in HCR and the GFR has progressively improved up to 48 mL/min. This report describes a notably renal function improvement in a patient with Light Chain Deposition Disease after therapy with BD followed by HDM, which can support this treatment as a future option for these patients.

Introduction

Light Chain Deposition Disease (LCDD) is a rare plasma cell dyscrasia characterized by deposition of monoclonal immunoglobulin light chains (LCs) in various organs.1 LCs are physiologically filtered by glomeruli, reabsorbed in proximal tubules and degraded in tubular cells, which makes kidney a prominent target for LC deposition.2-3 In this disease, monoclonal component is κ in virtually 100% of cases,1 which contrasts with the higher lambda frequency that is present in primary amyloidosis (AL). LCDD can be a primary disorder, although it is usually described associated to lymphoproliferative disorders or plasma cell dyscrasias (~50% with concurrent multiple myeloma). From the clinical point of view, most patients with LCDD present with nephrotic range proteinuria and rapid deteriorating renal function.4 Pathogenic background for nephrotic syndrome usually is predominant glomerular deposition (similar to AL amyloidosis), but some have predominant tubular deposition resulting in renal insufficiency with very high proteinuria.4

There is no standard treatment for patients with LCDD. Traditionally, specific treatment of LCDD has been considered to be ineffective in altering the course of the severe or end-stage renal failure.1,2,3 High dose therapy (HDT) and autologous peripheral blood stem cell transplantation APBSCT have been demonstrated to be efficient, even providing the possibility of renal disease reversibility in LCDD.5-10 However, the use of this strategy in patients with end-stage renal disease is of very high risk.11 Some reports have demonstrated that bortezomib and dexamethasone (BD) can be very effective in AL.12 Taking into account the similarities between AL and LCDD, some experiences have also shown that BD can be an option in LCDD.13 Accordingly, the combination of both strategies, BD and HDT, results very attractive, but no experience has been reported up to now in this specific situation.

Here we present a patient with an end-stage renal failure associated to LCDD in whom BD followed by HDT and APBSCT resulted in HCR and renal function recovery, allowing the patient to be treatment and dialysis independent for more than four years.

Case Report

ACEF, female, was diagnosed in January 2006 at 63 of age, as having a renal impairment. The Nephrology Dept. of our hospital observed a progressive increase in the creatinine levels from 2.2 mg/dL to 5.2 mg/dL (creatinine clearance: from 33 mL/min to 17 mL/min) in only 10 months. Since no clear explanation for the disorder was initially found, in November 2006 a renal biopsy was performed to elucidate the origin of the renal chronic failure, and a κ light chain deposition disease (kLCDD) diagnosed.

The patient was then admitted to Hematology for refining the diagnosis and to initiate appropriate treatment. The bone marrow aspirate demonstrated 9% of Bone marrow plasma cells (BMPC). Flow cytometry demonstrated a 6% bone marrow plasmacytosis with κ restriction in cytoplasmic immunoglobulins, as well as an aberrant immunophenotype (CD138+, CD38+++, CD56+, CD19+, CD45-) and a non-hyperdiploid DNA cell content. Among the plasma cell compartment, 90% of cells were aberrant, but 10% displayed normal immunophenotype (Figure 1). Conventional karyotype and FISH analysis for IgH translocations, Rb deletion and FCE deletion were normal either. Radiologic bone survey did not show any lytic lesion and serum calcium was normal. The serum creatinine at the moment was 6.4 mg/dL. Conventional serum electrophoresis and immunofixation failed to detect any monoclonal protein (Figure 2 and 3). Within a high amount of urinary proteins, a minimum peak was observed, and the immunofixation demonstrated a very weak monoclonal-like band in the anti-κ line and was scored as possible positive. In addition, the serum free light chain determination was highly favorable for κ, rendering a κ/λ ratio of 64.4, typically monoclonal. Accordingly, she was diagnosed as suffering Primary Light Chain Deposition Disease with renal impairment. Since the serum creatinine was higher than 5 mg/dL from the beginning, autologous stem cell transplantation (ASCT) was rejected as a first line therapy for the patient. Accordingly, after informed consent signing and legal authorization, patient started to receive bortezomib (1.3 mg/m2 on days 1, 4, 8 and 11) and dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12) in cycles every 21 days. After four courses, complete response (CR) according to the EBMT criteria14 was achieved. Then, a peripheral blood stem cell (PBSC) collection was performed after G-CSF mobilization (5 μg/Kg/12 h for 4 days). One successful apheresis procedure was carried out yielding a total of 2.55·106/Kg CD34+ cells. Two additional consolidation cycles of BD were administered and the transplant procedure was undergone with melphalan 140 mg/m2, since the filtration glomerular rate was below 25 mL/min. Pre-
transplant evaluation demonstrated that patient was in stringent CR according to the recently published criteria of the international myeloma working group (IMWG):\textsuperscript{15} negative serum and urine immunofixation, normal serum free light \(\kappa/\lambda\) ratio, less than 5% of BMPC by morphology and no monoclonal plasma cells by flow cytometry (0.14% of plasma cells, but all with normal immunophenotype). At this moment, the serum creatinine was 3.93 mg/dL, and no one dialytic procedure had been required at this point (Figure 4). The transplant was carried out without major complications with the exception of fluid overload on day +1, which required one peritoneal dialysis and intensive diuretic therapy. The patient was discharged on day +23 with normal peripheral blood counts. An evaluation performed at day +100, demonstrated a sustained stringent CR, an improvement in the clearance of creatinine to 28 mL/min and a serum creatinine of 3.05 mg/dL. Serial determinations demonstrated a progressive decrease of creatinine levels below 2.50 mg/dL and FGRs beyond 30 mL/min; more importantly, no hydroelectrolytic disturbances or fluid overloads have been noted and the arteriovenous fistula, initially created at diagnosis in 2006 as a preparation for chronic hemodialysis, has never been used. At this moment, almost five years after diagnosis, the LCDD is in sCR, the patient is free of dialysis, the creatinine level is of 2.31 mg/dL, and the FGR is 38 mL/min, with a creatinine clearance around 50 mL/min.

Discussion

The case here reported represents a success of the applicability of the new available strategies for both diagnosis and therapy of multiple myeloma (MM) to other monoclonal gammopathy related diseases, such it is Light Chain Deposition Diseases (LCDD). As far as the diagnosis is concerned, the use of the test for serum Free Light Chain assessment allowed confirming the presence of a monoclonal component in this patient. Without this assay, this patient would not have had an unequivocal assessment of systemic monoclonality. First, the monoclonal nature of the light chain deposition in the involved tissues (kidney in this case) is frequently very difficult to be assessed due to technical reasons.\textsuperscript{16-19} Second, the presence of a monoclonal light chain deposition in the kidney does not necessarily mean the presence of a systemic disease. First, the monoclonal nature of the light chain deposition in the involved tissues (kidney in this case) is frequently very difficult to be assessed due to technical reasons.\textsuperscript{16-19} Second, the presence of a monoclonal light chain deposition in the kidney does not necessarily mean the presence of a systemic disease. This is the reason of why up to 32% of these cases are traditionally considered as idiopathic,\textsuperscript{2} and why renal transplantation was considered in the past as a possible therapy for such patients.\textsuperscript{20} However, the recurrence of the light chain deposition in the transplanted kid-

\begin{figure}
\centering
\includegraphics[width=\textwidth]{immunohistochemistry.png}
\caption{Immunohistochemistry images of the bone marrow: positive dye for CD20 (A), CD138 (B), \(\kappa\) light chains (C) and negative dye for \(\lambda\) light chains (D).}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{electrophoresis.png}
\caption{Electrophoresis of serum (A) and of urine (B) sample of the patient.}
\end{figure}
ney is the rule, probably because of the absence of a correct accompanying systemic therapy against the clone responsible for the light chain production which is presumed to be sited at the bone marrow. Our patient would have been probably considered as a candidate for kidney transplantation if the absence of the FLC test, because of the lack of a definitive proof of systemic disease. In addition, flow cytometry (FCM) demonstrated the presence of a monoclonal plasma cell population in the bone marrow, a heavy argument favoring the existence of a systemic disease, although FCM is not yet considered in the criteria for initial diagnosis in monoclonal gammopathies.

In contrast, the use of APBSCT has demonstrated some good results in LCDD, which has also allowed the use of therapies using sequential stem cell and kidney transplants. Many treatments have been used for this disease with poor results (Alkylating agents with steroids) or increased mortality and significant toxicity (High-dose melphalan (HDM) with autologous stem cell transplantation (ASCT)). However, a serum creatinine >5 mg/dL is a very poor prognostic indicator for APBSCT, so this strategy should be done after some organic response of the disease is achieved. Bortezomib has shown significant activity and can be safely administered to MM patients with renal failure, which has prompted to develop combined strategies using bortezomib prior to APBSCT. In addition, bortezomib is also capable to provide hematologic and organ responses in primary amyloidosis. However, there is little experience with bortezomib in the treatment of LCDD, although the bortezomib mechanism of action seems to be targeted directed and there are some experiences that have indicated that bortezomib is able to reverse the renal failure linked to light chain deposition in amyloidosis. Actually, in some few cases Bortezomib has showed rapid hematologic responses, rapid decrease of proteinuria and some improvement of renal function, although duration of responses longer year and a half have not been demonstrated yet.

The use of the combined strategy with an induction to response with Bortezomib followed by a consolidation with high dose therapy and APBSCT has not been evaluated yet, especially in long-term follow-up. Our patient initially received 6 cycles of Bortezomib and Dexamethasone with an excellent hematologic response and a partial recovery of renal function. This condition allowed allocating the patient in a program of APBSCT with the patient in hematological CR and good renal condition to tolerate the procedure. Thus, the use of high dose melphalan and APBSCT consolidated the response for a very long time, so the patient is in continuous stringent CR for more than 4 years after its initial achievement.

In summary, this case illustrates that very efficient new therapeutic strategies developed for MM, such as the BD followed by APBSCT, can be an option for other rarer monoclonal gammopathy related disorders, such it is LCDD.

References

1. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30.
2. Pozzi C, D’Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003;42:1154-63.
3. Ronco P, Plaisier E, Mougenot B+, Aucouturier P. Immunoglobulin Light (Heavy)-Chain Deposition Disease: From Molecular Medicine to Pathophysiology-Driven Therapy. CI J Am Soc Nephrol 2006;1:1342-50.
4. Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990;112:455-64.
5. Heilman RL, Velosa JA, Holley KE, et al. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 1992;20:34-41.
6. Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dialysis Transpl 2008;23:2052-7.
7. Firkin E, Hill PA, Dwyer K, Gock H. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis 2004;44:551-5.
8. Weichman K, Dember LM, Prokaeva T, et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339-43.
9. Adam Z, Krejci M, Pour L, et al. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of liter-
19. Dey P. Role of ancillary techniques in diagnosing and subclassifying non-Hodgkin’s lymphomas on fine needle aspiration cytology. Cytopathology 2006;17:275-87.

20. Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004;43:147-53.

21. Alpers CE, Marchioro TI, Johnson RJ. Monoclonal immunoglobulin deposition disease in a renal allograft: probable recurrent disease in a patient without myeloma. Am J Kidney Dis 1989;13:418-23.

22. Short AK, O’Donoghue DJ, Riad HN et al. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol 2001;21:237-40.

23. Tanenbaum ND, Howell DN, Middleton JP, et al. Lambda light chain deposition disease in a renal allograft. Transplant Proc 2005;37:4289-92.

24. Alchi B, Nishi S, Iuchi S, et al. Recurrent light and heavy chain deposition disease after renal transplantation. Nephrol Dial Transplant 2005;20:1487-91.

25. Kuypers DR, Lerut E, Claes K, et al. Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab? Transpl Int 2007;20:381-5.

26. Larsen T, Hammer A, Jorgensen AO, et al. Recurrence of light-chain deposition disease after renal transplantation. Scand J Urol Nephrol 2008;42:187-8.

27. Harada K, Akai Y, Sakan H, et al. Resolution of mesangial light chain deposits 3 years after high-dose melphalan with autologous peripheral blood stem cell transplantation. Clin Nephrol 2010;74:384-8.

28. Petrakis I, Stylianou K, Mavroeidii V, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant 2010;25:2020-3.

29. Barracough KA, Dowling JP, Schraver AP, Perry GJ. Sequential autologous peripheral blood stem cell transplantation and kidney transplantation of light chain deposition disease. Nephrol Dial Transplant 2007;22:1268-9.

30. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007;20:701-15.

31. Dimopoulos MA, Verpos E, Chanani-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-84.

32. Li J, Zhou DB, Jiao L, et al. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymph Myeloma 2009;9:394-8.

33. Dimopoulos MA, Roussou M, Gavriatopolou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymph Myeloma. 2009;9:302-6.

34. Siniscalchi A, Dentamaro T, Perrotti A, et al. Bortezomib-based therapy as induction regimen of an autograft program in frontline treatment of multiple myeloma with end-stage renal disease. Ann Hematol 2010;89:821-2.

35. Kastritis E, Michalopoulos K, Gavriatopolou M, et al. Retrospective Study of the Efficacy of Bortezomib in Primary Systemic Amyloidosis. Blood (ASH Annual Meeting Abstracts) 2009;114:4953.

36. Lamm W, Willenbacher W, Zojer N, et al. Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis. Blood (ASH Annual Meeting Abstracts) 2009;114:2871.

37. Reece DE, Sanchonawa V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase I dose-escalation study. Blood 2009;114:1489-97.

38. Ying WZ, Wang PX, Aaron KJ, et al. Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism. Blood 2011;117:1301-7.

39. Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010;28:24635-41.

40. Kastritis E, Mitkou M, Gavriatopolou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009;94:300-2.

41. Gharwan H, Truica C. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol 2011. [Epub ahead of print]